Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021

作者：Gong Feng, Giovanni Targher, Christopher D. Byrne, Yusuf Yılmaz, Vincent Wai‐Sun Wong, Cosmas Rinaldi Adithya Lesmana, Leon A. Adams, Jérôme Boursier, George Papatheodoridis, Mohamed El‐Kassas, Nahúm Méndez‐Sánchez, Silvia Sookoian, Laurent Castéra, Wah‐Kheong Chan, Feng Ye, Sombat Treeprasertsuk, Helena Cortez‐Pinto, Hon Ho Yu, Won Kim, Manuel Romero‐Gómez, Atsushi Nakajima, Khin Maung Win, Seung Up Kim, Adriaan G. Holleboom, Giada Sebastiani, Ponsiano Ocama, John Ryan, Monica Lupșor‐Platon, Hasmik Ghazinyan, Mamun Al-Mahtab, Saeed Hamid, Nilanka Perera, Khalid Alswat, Qiuwei Pan, Michelle T. Long, Isakov Va, Man Mi, Marco Arrese, Arun J. Sanyal, Shiv Kumar Sarin, Nathalie C. Leite, Luca Valenti, Philip N. Newsome, Hannes Hagström, Salvatore Petta, Hannele Yki‐Järvinen, Jörn M. Schattenberg, Marlén Castellanos, Isabelle Leclercq, Gulnara Aghayeva, Abdel‐Naser Elzouki, Ali Tumi, Ala I. Sharara, Asma Labidi, Faisal M. Sanai, Khaled Matar‎, Maen Almattooq, Maisam Akroush, Mustapha Benazzouz, Nabil Debzi, Maryam Alkhatry, Salma Barakat, Said A. Al‐Busafi, John Rwegasha, Wah Yang, Adwoa Agyei‐Nkansah, Christopher Opio, Mohammadjavad Sotoudeheian, Yu Jun Wong, Jacob George, Ming‐Hua Zheng · 发表于：JHEP Reports · 年份：2024 · DOI：10.1016/j.jhepr.2024.101271 · 被引用次数：113 · 研究领域：Liver Disease Diagnosis and Treatment、Liver Disease and Transplantation、Diabetes, Cardiovascular Risks, and Lipoproteins

Background & Aims: This study used the Global Burden of Disease data (2010-2021) to analyze the rates and trends of point prevalence, annual incidence, and years lived with disability (YLDs) for metabolic dysfunction-associated steatotic liver disease (MASLD) in 204 countries. Methods: Total numbers and age-standardized rates per 100,000 population for MASLD prevalence, annual incidence, and YLDs were compared across regions and countries by age, sex, and sociodemographic index (SDI). Smoothing spline models were used to evaluate the relationship between the burden of MASLD and SDI. Estimates were reported with uncertainty intervals (UI). Results: 14,310.6 cases per 100,000 population). Prevalence peaked at ages 45-49 for men and 50-54 for women. Kuwait (32,312.2 cases per 100,000 people; 95% UI: 29,947.1-34,839.0), Egypt (31,668.8 cases per 100,000 people; 95% UI: 29,272.5-34,224.7), and Qatar (31,327.5 cases per 100,000 people; 95% UI: 29,078.5-33,790.9) had the highest prevalence rates in 2021. The largest increases in age-standardized point prevalence estimates from 2010 to 2021 were in China (16.9%, 95% UI 14.7%-18.9%), Sudan (13.3%, 95% UI 9.8%-16.7%) and India (13.2%, 95% UI 12.0%-14.4%). MASLD incidence varied with SDI, peaking at moderate SDI levels. Conclusions: MASLD is a global health concern, with the highest prevalence reported in Kuwait, Egypt, and Qatar. Raising awareness about risk factors and prevention is essential in every country, especially in China, Sud...